Jia Junpeng, Fu Mei, Ji Wenxin, Xiong Ningna, Chen Peng, Lin Jian, Yang Qian
MOE Joint International Research Laboratory of Animal Health and Food Safety, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu, China.
Beijing Enhalor International Tech Co., Ltd., Beijing, China.
Microbiol Spectr. 2024 Oct 29;12(12):e0091824. doi: 10.1128/spectrum.00918-24.
Surfactin, a lipopeptide biosurfactant produced by spp., has emerged as a promising bioactive compound due to its potent inhibitory effects on bacterial and viral pathogens. This showcases its potential as a non-antibiotic strategy for managing infectious diseases. Our investigation reveals that surfactin administration significantly promotes weight gain and improves immune organ indices in mice, reflecting enhanced immunity and gut health. Surfactin augments phagocytic function in peritoneal macrophages and boosts proliferative responses in splenic lymphocytes post-chicken red blood cell immunization. Furthermore, it increases intestinal villi height, indicative of superior nutrient absorption. It elevates mucin secretion and expression of intestinal mucosal proteins, such as secretory IgA, Muc1, and Muc2, and tight junction proteins claudin-1, occludin, and Zo-1 in the jejunum and colon. Crucially, surfactin modifies the gut microbiota composition by reducing populations and ameliorating cyclophosphamide-induced gut dysbiosis. Our data suggest that oral surfactin could be a valuable therapeutic modality to alleviate immune suppression and gut damage, proposing a new pathway for immunomodulatory treatment.
The potential of surfactin as a microbial surfactant extends beyond its surfactant properties, impacting immune regulation and gut health. As the need for alternatives to traditional antibiotics continues to grow, surfactin's ability to enhance host defense mechanisms against common pathogens without directly targeting them with antibiotics offers a strategic advantage. Understanding how surfactin shapes the immune landscape and the gut microbiome can inform innovative interventions against immunosuppression and intestinal impairment, particularly in contexts such as cyclophosphamide-induced toxicity.
表面活性素是由 种产生的一种脂肽生物表面活性剂，由于其对细菌和病毒病原体具有强大的抑制作用，已成为一种有前景的生物活性化合物。这展示了其作为管理传染病的非抗生素策略的潜力。我们的研究表明，给予表面活性素可显著促进小鼠体重增加并改善免疫器官指数，反映出免疫力和肠道健康得到增强。表面活性素可增强腹膜巨噬细胞的吞噬功能，并在鸡红细胞免疫后促进脾淋巴细胞的增殖反应。此外，它可增加肠绒毛高度，表明营养吸收更佳。它可提高空肠和结肠中粘蛋白的分泌以及肠道粘膜蛋白（如分泌型 IgA、Muc1 和 Muc2）的表达，以及紧密连接蛋白claudin-1、occludin 和 Zo-1 的表达。至关重要的是，表面活性素通过减少 种群数量并改善环磷酰胺诱导的肠道菌群失调来改变肠道微生物群组成。我们的数据表明，口服表面活性素可能是缓解免疫抑制和肠道损伤的一种有价值的治疗方式，为免疫调节治疗提出了一条新途径。
表面活性素作为一种微生物表面活性剂的潜力超出了其表面活性特性，对免疫调节和肠道健康产生影响。随着对传统抗生素替代品的需求持续增长，表面活性素在不直接用抗生素靶向常见病原体的情况下增强宿主防御机制的能力具有战略优势。了解表面活性素如何塑造免疫格局和肠道微生物群可以为针对免疫抑制和肠道损伤的创新干预措施提供信息，特别是在环磷酰胺诱导毒性等情况下。
